PT Millennium Pharmacon International Tbk Stock

Equities

SDPC

ID1000072804

Pharmaceuticals

End-of-day quote INDONESIA S.E. 06:00:00 2024-05-29 pm EDT 5-day change 1st Jan Change
139 IDR +0.72% Intraday chart for PT Millennium Pharmacon International Tbk -0.71% -12.03%
Sales 2022 3,201B 198M Sales 2023 3,364B 209M Capitalization 201B 12.48M
Net income 2022 24.46B 1.52M Net income 2023 33.09B 2.05M EV / Sales 2022 0.32 x
Net Debt 2022 597B 36.99M Net Debt 2023 699B 43.34M EV / Sales 2023 0.27 x
P/E ratio 2022
17.3 x
P/E ratio 2023
6.08 x
Employees 1,168
Yield 2022
0.6%
Yield 2023
-
Free-Float 14.98%
More Fundamentals * Assessed data
Dynamic Chart
PT Millennium Pharmacon International Tbk Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
PT Millennium Pharmacon International Tbk Reports Earnings Results for the Full Year Ended December 31, 2023 CI
PT Millennium Pharmacon International Tbk Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
PT Millennium Pharmacon International Tbk Reports Earnings Results for the Half Year Ended June 30, 2023 CI
PT Millennium Pharmacon International Tbk Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
PT Millennium Pharmacon International Tbk Reports Earnings Results for the Full Year Ended December 31, 2022 CI
PT Millennium Pharmacon International Tbk Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
PT Millennium Pharmacon International Tbk Reports Earnings Results for the Half Year Ended June 30, 2022 CI
PT Millennium Pharmacon International Tbk Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
PT Millennium Pharmacon International Tbk Reports Earnings Results for the Full Year Ended December 31, 2021 CI
PT Millennium Pharmacon International Tbk Seeks Inorganic Growth Opportunities CI
PT Millennium Pharmacon International Tbk Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
PT Millennium Pharmacon International Tbk Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Pt Millennium Pharmacon International Tbk Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
PT Millennium Pharmacon International Tbk acquired 15% stake in PT. Errita Pharma from PT Sinar Niaga Mujur for IDR 54 billion. CI
More news
1 day+0.72%
1 week-0.71%
3 months-4.79%
6 months-15.76%
Current year-12.03%
More quotes
1 week
136.00
Extreme 136
140.00
1 month
134.00
Extreme 134
144.00
Current year
133.00
Extreme 133
175.00
1 year
128.00
Extreme 128
214.00
3 years
107.00
Extreme 107
396.00
5 years
62.00
Extreme 62
396.00
10 years
62.00
Extreme 62
396.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 -
Director of Finance/CFO - -
Comptroller/Controller/Auditor - -
Members of the board TitleAgeSince
Chairman 67 21-04-28
Chief Executive Officer 55 -
Director/Board Member 49 21-10-31
More insiders
Date Price Change Volume
24-05-29 139 +0.72% 133 600
24-05-29 138 -1.43% 807,500
24-05-28 140 +0.72% 91,100
24-05-27 139 -0.71% 131,900
24-05-22 140 -0.71% 209,500

End-of-day quote INDONESIA S.E., May 29, 2024

More quotes
PT Millennium Pharmacon International Tbk is an Indonesia-based company primarily engaged in distributing pharmaceutical products. The Company’s segments include Prescription Medicine, Medical Devices, and Non-prescription Medicine. The Company’s products include Atangin JRG liquid, Tissue Lovers for Man, Antangin Black Seed, OB Herbs, Safe Care Aromatherapy, Lansoprazole Nulab, MMPSG065 Metra Surgical Glove POW 6.5, and 2TRGPSG070 Tro-Sensosurge Sterile Glove 7.0 pcs. A Tangin Jrg Liquid is an herbal syrup for colds with the main ingredients ginger, royal jelly and ginseng. Tissue Lovers For Man is a refreshing wet wipe, which cleanses the skin of sensitive areas. Antangin Habbatussauda is an herbal syrup containing black seed, meniran and ginger. The Company distributes its products to Java, Bali, Sumatera, Kalimantan and Sulawesi islands.
More about the company